Evolution and emergence of therapeutic monoclonal antibodies what cardiologists need to know

Circulation

Volumn 127, Issue 22, 2013, Pages 2222-2230

  Foltz, Ian N ^a   Karow, Margaret ^b   Wasserman, Scott M ^b  

^a Amgen British Columbia   (Canada)

^b AMGEN INC   (United States)

Author keywords

Antibodies; Heart diseases; Hypercholesterolemia; Monoclonal; Pcsk9 protein

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; ALIROCUMAB; BASILIXIMAB; BELIMUMAB; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CANAKINUMAB; CERTOLIZUMAB PEGOL; CETUXIMAB; DENOSUMAB; ECULIZUMAB; GOLIMUMAB; IBRITUMOMAB TIUXETAN; INFLIXIMAB; IPILIMUMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; OFATUMUMAB; OKT 3; OMALIZUMAB; PANITUMUMAB; PERTUZUMAB; RITUXIMAB; TOCILIZUMAB; TOSITUMOMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNINDEXED DRUG; USTEKINUMAB;

ACUTE GRAFT REJECTION; ALLERGIC ASTHMA; ANKYLOSING SPONDYLITIS; ANTIBODY STRUCTURE; ARTICLE; BOLUS INJECTION; BREAST CANCER; CASTRATION RESISTANT PROSTATE CANCER; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CINCA SYNDROME; COLORECTAL CANCER; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; ERYTHEMA; FEVER; GLIOBLASTOMA; GRAFT REJECTION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMOLYTIC UREMIC SYNDROME; HODGKIN DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPOTENSION; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; ISCHEMIC HEART DISEASE; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY CARCINOMA; KIDNEY GRAFT REJECTION; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; MELANOMA; META ANALYSIS (TOPIC); MICROSCOPIC POLYANGIITIS; MULTIPLE SCLEROSIS; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHASE 2 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PRURITUS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RASH; RHEUMATOID ARTHRITIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STOMACH ADENOCARCINOMA; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; ULCERATIVE COLITIS; WEGENER GRANULOMATOSIS;

ANTIBODIES, MONOCLONAL; HEART DISEASES; HYPERCHOLESTEROLEMIA; PCSK9 PROTEIN;

ANIMALS; ANTIBODIES, MONOCLONAL; CARDIOLOGY; HEART DISEASES; HUMANS; HYBRIDOMAS; MICE; MICE, TRANSGENIC;

EID: 84878550146     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.002033     Document Type: Article

References (76)

1. Haurum JS. Recombinant polyclonal antibodies: the next generation of antibody therapeutics? Drug Discov Today. 2006;11:655-660.
2. Edelman GM, Benacerraf B, Ovary Z, Poulik MD. Structural differences among antibodies of different specificities. Proc Natl Acad Sci USA. 1961;47:1751-1758.
3. Porter RR. Chemical Structure Of Gamma-Globulin And Antibodies. Br Med Bull. 1963;19:197-201.
4. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495-497.
5. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol. 2010;10:345-352.
6. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 2010;9:767-774.
7. Zhou H, Mascelli MA. Mechanisms of monoclonal antibody-drug interactions. Annu Rev Pharmacol Toxicol. 2011;51:359-372.
8. Kolar GR, Capra DJ. Immunoglobulins: structure and function. In: Paul WE, ed. Fundamental Immunology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003.
9. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:493-507.
10. Weiner LM. Fully human therapeutic monoclonal antibodies. J Immunother. 2006;29:1-9.
11. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. 2001;38:17-23. (Pubitemid 32194591)
12. Lonberg N. Human antibodies from transgenic animals. Nat Biotechnol. 2005;23:1117-1125. (Pubitemid 41486393)
13. Lonberg N. Fully human antibodies from transgenic mouse and phage display platforms. Curr Opin Immunol 2008;20:450-459.
14. Kim SJ, Park Y, Hong HJ. Antibody engineering for the development of therapeutic antibodies. Mol Cells. 2005;20:17-29.
15. Hochholzer W, Giugliano RP. Lipid lowering goals: back to nature? Ther Adv Cardiovasc Dis. 2010;4:185-191.
16. Michnick SW, Sidhu SS. Submitting antibodies to binding arbitration. Nat Chem Biol. 2008;4:326-329. (Pubitemid 351693997)
17. st ed. New York, NY: Springer; 2011:534-568.
18. Robinson MK, Borghaei H, Adams GP, Weiner LM. Monoclonal antibodies. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. Vol 1. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:537-548.
19. 2. Cancer Res. 2007;67:11991-11999.
20. Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, Do YR, Shin HJ, Kim MK, Hyun MS, Sohn SK. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood. 2006;108:2720-2725.
21. Adcetris® (brentuximab vedotin) [full prescribing information]. Bothell, WA: SeattleGenetics; 2011.
22. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93:2645-2668. (Pubitemid 39506617)
23. Vugmeyster Y, Xu X, Theil FP, Khawli LA, Leach MW. Pharmacokinetics and toxicology of therapeutic proteins: advances and challenges. World J Biol Chem. 2012;3:73-92.
24. Tabrizi M, Bornstein GG, Suria H. Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J. 2010;12:33-43.
25. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11:81-88. (Pubitemid 43227856)
26. Gabathuler R. Approaches to transport therapeutic drugs across the bloodbrain barrier to treat brain diseases. Neurobiol Dis. 2010;37:48-57.
27. Tabrizi MA, Roskos LK. Preclinical and clinical safety of monoclonal antibodies. Drug Discov Today. 2007;12:540-547. (Pubitemid 47031663)
28. Humira® (adalimumab) [full prescribing information]. Abbott Park, IL: Abbott Laboratories; 2011.
29. Remicade® (infliximab) [full prescribing information]. Horsham, PA: Janssen Biotech, Inc; 2011.
30. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9:325-338.
31. Mazzaferri EL Jr, Young JJ. Abciximab: a review and update for clinicians. Expert Rev Cardiovasc Ther. 2008;6:609-618.
32. Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf. 2008;31:459-467. (Pubitemid 351695459)
33. Breslin S. Cytokine-release syndrome: overview and nursing implications. Clin J Oncol Nurs. 2007;11(suppl):37-42.
34. Vultaggio A, Maggi E, Matucci A. Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. Curr Opin Allergy Clin Immunol. 2011;11:262-268.
35. Hausmann OV, Seitz M, Villiger PM, Pichler WJ. The complex clinical picture of side effects to biologicals. Med Clin North Am. 2010;94:791-804, xi.
36. Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods. 2005;36:3-10. (Pubitemid 40558811)
37. Straarup EM, Fisker N, Hedtjärn M, Lindholm MW, Rosenbohm C, Aarup V, Hansen HF, Ørum H, Hansen JB, Koch T. Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res. 2010;38:7100-7111.
38. Benucci M, Saviola G, Manfredi M, Sarzi-Puttini P, Atzeni F. Tumor necrosis factors blocking agents: analogies and differences. Acta Biomed. 2012;83:72-80.
39. Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Fam Physician. 2008;77:311-319. (Pubitemid 351206593)
40. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84:548-558.
41. Kleinberg M, Mosdell KW. Current and future considerations for the new classes of biologicals. Am J Health Syst Pharm. 2004;61:695-708; quiz 709.
42. Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov. 2012;11:527-540.
43. Azrin MA. The use of antibodies in clinical cardiology. Am Heart J. 1992;124:753-768.
44. Hudis CA. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39-51. (Pubitemid 47026733)
45. Segovia J, Rodríguez-Lambert JL, Crespo-Leiro MG, Almenar L, Roig E, Gómez-Sánchez MA, Lage E, Manito N, Alonso-Pulpón L. A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. Transplantation. 2006;81:1542-1548. (Pubitemid 43890891)
46. Delgado JF, Vaqueriza D, Sánchez V, Escribano P, Ruiz-Cano MJ, Renes E, Gómez-Sanchez MA, Cortina JM, de la Calzada CS. Induction treatment with monoclonal antibodies for heart transplantation. Transplant Rev (Orlando). 2011;25:21-26.
47. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, Van de Werf F, Antman EM, Topol EJ. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. 2005;293:1759-1765.
48. Hassan AK, Liem SS, van der Kley F, Bergheanu SC, Wolterbeek R, Bosch J, Bootsma M, Zeppenfeld K, van der Laarse A, Atsma DE, Jukema JW, Schalij MJ. In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: results from the Leiden MISSION acute myocardial infarction treatment optimization program. Catheter Cardiovasc Interv. 2009;74:335-343.
49. Thiele H, Wöhrle J, Hambrecht R, Rittger H, Birkemeyer R, Lauer B, Neuhaus P, Brosteanu O, Sick P, Wiemer M, Kerber S, Kleinertz K, Eitel I, Desch S, Schuler G. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial. Lancet. 2012;379:923-931.
50. De Luca G, Ucci G, Cassetti E, Marino P. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis. J Am Coll Cardiol. 2009;53:1668-1673.
51. Abifadel M, Varret M, Rabés JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derré A, Villéger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154-156. (Pubitemid 36666925)
52. Chan DC, Lambert G, Barrett PH, Rye KA, Ooi EM, Watts GF. Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism? Clin Chem. 2009;55:2049-2052.
53. Piper DE, Jackson S, Liu Q, Romanow WG, Shetterly S, Thibault ST, Shan B, Walker NP. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure. 2007;15:545-552. (Pubitemid 46702689)
54. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-1272.
55. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37:161-165.
56. Dias CS, Shaywitz AJ, Wasserman SM, Smith BP, Gao B, Stolman DS, Crispino CP, Smirnakis KV, Emery MG, Colbert A, Gibbs JP, Retter MW, Cooke BP, Uy ST, Matson M, Stein EA. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol. 2012;60:1888-1898.
57. Koren MJ, Scott R, Kim JB, Knusel B, Liu T, Lei L, Bolognese M, Wasserman SM. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, doubleblind, placebo-controlled, phase 2 study. Lancet. 2012;380:1995-2006.
58. Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012;380:2007-2017.
59. Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, Stein EA. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012;126:2408-2417.
60. Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, Wasserman SM, Stein EA. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012;308:2497-2506.
61. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59:2344-2353.
62. Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, Lisbon E, Gutierrez M, Webb C, Wu R, Du Y, Kranz T, Gasparino E, Swergold GD. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366:1108-1118.
63. Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, Wu R, Pordy R. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380:29-36.
64. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367:1891-1900.
65. Gumbiner B, Udata C, Joh T, Liang H, Wan H, Shelton D, Forgues P, Billotte S, Pons J, Baum C, Garzone P. The effects of single dose administration of RN316 (PF-04950615), a humanized IgG2a monoclonal antibody binding proprotein convertase subtilisin kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin [abstract 13322]. Presented at: American Heart Association Scientific Sessions 2012; November 3-7, 2012; Los Angeles, CA.
66. Gumbiner B, Udata C, Joh T, Liang H, Wan H, Shelton D, Forgues P, Billotte S, Pons J, Baum C, Garzone P. The effects of multiple dose administration of RN316 (PF-04950615), a humanized IgG2a monoclonal antibody binding proprotein convertase subtilisin kexin type 9, in hypercholesterolemic subjects [abstract 13524]. Presented at: American Heart Association Scientific Sessions 2012; November 3-7, 2012; Los Angeles, CA.
67. National Institutes of Health. A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease [online database]. http://www.clinicaltrials.gov/ct2/ show/NCT01609140?term=mpsk3169A&rank=1. Accessed January 21, 2013.
68. Abbate A, Van Tassell BW, Biondi-Zoccai GG. Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events. BioDrugs. 2012;26:217-233.
69. Galea J, Armstrong J, Gadsdon P, Holden H, Francis SE, Holt CM. Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol. 1996;16:1000-1006. (Pubitemid 26266899)
70. Correia LC, Andrade BB, Borges VM, Clarêncio J, Bittencourt AP, Freitas R, Souza AC, Almeida MC, Leal J, Esteves JP, Barral-Netto M. Prognostic value of cytokines and chemokines in addition to the GRACE Score in non-ST-elevation acute coronary syndromes. Clin Chim Acta. 2010;411:540-545.
71. Kilic T, Ural D, Ural E, Yumuk Z, Agacdiken A, Sahin T, Kahraman G, Kozdag G, Vural A, Komsuoglu B. Relation between proinflammatory to anti-inflammatory cytokine ratios and long-term prognosis in patients with non-ST elevation acute coronary syndrome. Heart. 2006;92:1041-1046. (Pubitemid 44125212)
72. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162:597-605.
73. XOMA announces Servier has initiated a proof-of-concept gevokizumab study in patients with a history of acute coronary syndrome [press release]. Berkeley, CA: Xoma. November 29, 2012. http://investors.xoma.com/releasedetail. cfm?ReleaseID=723905. Accessed January 21, 2013.
74. Clinical development pipeline. Lilly Web site. http://lilly.com/ SiteCollectionDocuments/Pipeline/Clinical%20Development%20Pipeline/index. html#PhaseI. Accessed January 21, 2013.
75. National Institutes of Health. A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery. January 15, 2013. http://clinicaltrials.gov/show/NCT01245634. Accessed January 21, 2013.
76. Announcement of topline results from the GLACIER study [press release]. Lund, Sweden: BioInvent. http://www.bioinvent.se/media-centre/pressreleases/ release.aspx?releaseid=682959. Accessed January 21, 2013.